We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Brazil’s antitrust watchdog has fined Eli Lilly and its local affiliate $11.7 million for filing contradictory and misleading lawsuits in Brazilian courts to maintain exclusive rights to its cancer drug Gemzar. Read More
Lawmakers in the House introduced a bipartisan bill that would prevent brand drugmakers from thwarting competition by using restricted distribution networks to deny generics and biosimilars makers access to product samples they need to obtain FDA marketing approval. Read More
Competition from generic drugs allowed European healthcare systems and patients to save more than $100 billion last year, a new report shows. Generics competition nearly doubled access to drugs across seven key therapy areas: angiotensin II antagonists, antiepileptics, antidepressants, antipsychotics, antiulcerants, cholesterol regulators and oral antidiabetics, according to an IMS Institute for Healthcare Informatics report released earlier this month. Read More
Oncology drugmaker Delcath Systems has received orphan drug designation for melphalan to treat intrahepatic cholangiocarcinoma, or ICC, a cancer of the bile duct that arises within the liver. Read More
Insects found in IV solutions have forced Baxter International to voluntarily recall two lots of product, the firm’s seventh recall of an intravenous solution since December 2013. Read More